




| 17 | Audit Types |
|----|--|
| | Retrospective - after billing Advantages: Simple, documentation is complete, refined sample Disadvantages: Processing findings, may not be timely, billing adjustments may be required |
| | Prospective - before billing Advantages: Timely, avoid billing adjustments Disadvantages: May hold up billing, sample may be limited More difficult to complete |
| KW | © 2017, Kelly Willenberg, LLC |











| \mathcal{I} | Area of Risk | Why this is a Risk | | | | |
|---------------|--|--|--|--|--|--|
| | Budget development and approval | Lack of consistency | | | | |
| | Registration of research subjects | Lack of subject tracking mechanism, billing errors | | | | |
| | Charge capture/billing for research related services | No process for tracking or reporting | | | | |
| | Document Concordance | Inconsistent documents lead to billing errors | | | | |
| | Process for resolving billing inquiries | Follow through not performed | | | | |


| | ²³ Areas | s to Watch | |
|----|--|--|--|
| | Inadequate financial accounting | Poor budget process, lack of proper accounting and invoicing to Sponsors | September 30, 2013 |
| | Research subjects not identified | Claims lack proper research coding, dx, modifiers, CCs, and NCT # on claim | Emory Settles FCA Case, Cites Challenges of Billing for Trials Simmering tensions over the sharing of revenues from clinical trials set in motion a cortice |
| | Charge capture/billing for research related services and routine costs, study drugs & devices | Charge segregation occurring between research and payer or Medicare and Medicare Advantage | ulumately do Emory University's recent \$1.5 million False Claims Act settlement. That's the picture painted by an unscaled whistleblower complaint filed in December Accused of improperty by: |
| | No monitoring of billing inquiries | Communication on denials management not thorough or lack of attention to detail | Accused of improperly billing Medicare, Medicaid and TRCARE for services that should have been reim- bursed by the sponsors of cancer and other studies, Emo- try acknowledged only that "billing errors occurred," Whistleblower Elizabeth Elliott worked for Emory finance manager at Emory's Office of Clinical Research |
| KW | , | 2017, Kelly Willenberg, LLC | 9 Unical Research |


Г










































| | | | Billin Cov | | | | | | | rt ⁻ | wi | th | th | 9 |
|---|------------------------------|--|---|-------------------------|----------------------------|---------------|-------------------------|----------------------|---|-----------------|----------------|----------------|---------------|---|
| | | This Coverage A | Analysis is intended a | s a general guid | leline for use in | determining v | which items and s | ervices are bi | illable to a 3ro | l Party Paye | r. All items a | nd services th | at are billab | e to a 3rd Party Payer must be supported by m |
| | C | Protocol Related Items and | CPT / HCPCS | Active Monitoring Phase | | | | | | | | | | |
| | \int | Services | | ≤ 60 days prior to | At time of registration | Surgery | Adjuvant Chemotherap | Radiation Therapy | Observatio n (6 | Year 1.5 | Year 2.5 | Year 3.5 | Year 4.5 | Comments and Justific |
| | | CBC with Diff. & Platelets | 85025 | м | | | | | | | | | | NCCN guidelines for Breast Cancer (v2.2015) si Coverage also generally supported under NCD Medical records must document medical neces |
| | | Bilateral Mammogram | 77056, 770561 | м | | | | | м | м | м | м | м | NCCN guidelines for Breast Cancer (v2.2015) so the work-up and surveillance period. Medical records must document medical neces |
| | | Bilateral MRI of Breasts | 77059, A9952, 96374 | м | | | | | | | | | | NCCCR puidelines for Breast Cancer (v2 2015)- MRI during the work-up period. May be used fi deline extent of cancer or presence of multifoc the ignitiateral breast, or as screening of the co time of initial diagnosis (category 28). There a demonstrate that the use of NRI to facilitate to improves local recurrence or survival. Medica medical necessity |
| | | Biopsy of each suspicious breast lesion | 88307, 88305, 19101, 19100, 19081-19186 | м | | | | | | | | | | NCCCN guidelines for Breast Cancer (v2.2015) : biopsy during the work-up for breast cancer. Medical records must document medical neces |
| Dptional research blood 36415, 36591, S S S S S S S S S S S S S S S S S S S | | | | | | | | | Research purposes only; bill to sponsor | | | | | |
| K | © 2017, Kelly Wilenberg, LLC | | | | | | | | | | | | | |










































| 53 | Clinical Trial Research Order Form |
|----|--|
| | Date of Service: |
| KW | Title: Pi: IRB ±: Sponsor: Project ±: INDIDE ±: Clinical Trials.gov ±: |


| 54 | Clinical Trial Research Order Form |
|----|---|
| | Services Procedures CP 1 Code Bill to Study Services Lab Services CP 1 Code Data Collection only - no protocol stipulated |
| KW | Date/Time Physician / Prescriber Signature MD ID# Date/Time Date/Time 12/24 Hour Chart Check RN PrintInitial Date/Time RN Signature/Print Validation of Correct Transcription Date/Time |















































































| 83 | The Audit |
|----|---|
| | Look for denials or partial payments There may be Local Coverage Determinations that were not accounted for when the study was started Also important in drug studies Look at study accounts in relation to the budgets and reconciliation |
| | Check for high residuals Confirm that a signed copy of the ICF is in the Medical Records and in the pharmacy records if study drug is being used |
| KW | © 2017, Kelly Willenberg, LLC |

